Error: The server you are trying to reach is temporarily unavailable.

Our website is currently unavailable.

We do our best to prevent this from happening, and we're working to fix the problem.


If you have an emergency, please dial 911.
The OHSU hospital is open 365 days a year, 24 hours a day.


The OHSU and Doernbecher Emergency Departments are located at:
3181 S.W. Sam Jackson Park Rd.
Portland, OR 97239-3098


Emergency: 911
Main Operator: 503 494-8311
Web site feedback:

Categories | Inventors

U87MG Cell Lines Expressing CD4, CD4 and CCR5, or CD4 and CXCR4


OHSU # 0422


Technology Overview
HIV-1 isolates infect cells that express CD4 as well as a coreceptor.  The predominant coreceptor for T-cell-tropic isolates is CCR5.  Human astroglioma U87MG cells lack coreceptors for HIV-1, so that even U87MG-CD4 cells are resistant to infection.  U87MG-CD4/CXCR4 and U87MG-CD4/CCR5 cells were prepared by transfection of a U87MG-CD4 cell clone with pcDNA3 vectors that contained cDNAs for CXCR4 or CCR5.  Technology #0422, U87MG-CD4/CXCR4 cells are highly susceptible to T-cell-tropic HIV-1 isolates, whereas the U87MG-CD4/CCR5 cells are susceptible to macrophage-trophic isolates. Both lines are highly susceptible to primary patient as well as laboratory-adapted HIV-1 isolates. 


By screening new HIV-1 isolates for infectivity in these 3 cell clones, decisions can be made regarding the coreceptor usage of the viruses. The cells will also be useful for screening drugs targeted to the coreceptors. Thus, toxic drugs would inhibit viruses that grow in any of the clones, whereas drugs specific for CXCR4 or CCR5 would only inhibit HIV-1 isolates that grow in the cell clones that express these coreceptors.


Inventor Profile
Dr. David Kabat is a Professor in the Biochemistry and Molecular Biology Department at Oregon Health & Science University.  He received his B.S. from Brown University and Ph.D. from the California Institute of Technology. Prior to coming to OHSU, Dr. Kabat held positions at MIT and the University of Oregon Medical School, now OHSU.


Kozak et al. J. Virology 1997, 71(2):873-882


Licensing Opportunity
These three cell lines are available for non-exclusive licensing as a group or individually.



For more information, contact:

Trina Voss
Technology Development Manager

(terms)  $0.00